High Tower Advisors, LLC Zynerba Pharmaceuticals, Inc. Transaction History

High Tower Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$0.86 - $2.06 $14,319 - $34,299	16,650 New	16,650 $20,000
Q4 2020 Feb 10, 2021	SELL	$3.27 - $4.64 $115,408 - $163,759	-35,293 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$3.23 - $4.3 $20,349 - $27,090	-6,300 Reduced 15.15%	35,293 $117,000
Q1 2020 May 21, 2020	SELL	$2.9 - $6.16 $6,525 - $13,860	-2,250 Reduced 5.13%	41,593 $159,000
Q4 2019 Feb 14, 2020	SELL	$5.61 - $8.57 $140 - $214	-25 Reduced 0.06%	43,843 $265,000
Q3 2019 Nov 12, 2019	SELL	$7.56 - $15.44 $152,145 - $310,730	-20,125 Reduced 31.45%	43,868 $333,000
Q2 2019 Aug 13, 2019	SELL	$5.4 - $15.5 $170,100 - $488,250	-31,500 Reduced 32.99%	63,993 $867,000
Q1 2019 May 15, 2019	BUY	$3.6 - $6.22 $39,600 - $68,420	11,000 Added 13.02%	95,493 $518,000
Q4 2018 Feb 14, 2019	SELL	$2.89 - $7.91 $20,952 - $57,347	-7,250 Reduced 7.9%	84,493 $251,000
Q3 2018 Nov 09, 2018	BUY	$5.59 - $10.45 $46,676 - $87,257	8,350 Added 10.01%	91,743 $748,000
Q4 2017 Feb 14, 2018	BUY	$8.69 - $14.59 $724,685 - $1.22 Million	83,393	83,393 $1.05 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.